Christine Adreani
Stephen Martin
As Head of Global Pharmaceutical R&D at Boehringer Ingelheim Animal Health Stephen Martin has:
- Lead functions responsible for discovering, developing, and gaining world-wide marketing authorizations for animal health medicines and health products.
- Lead the global R&D functions that support manufacturing of pharmaceutical drugs. Includes functions responsible for analytical methods, formulation, technical transfer and investigations for development and commercial products.
- Implemented and lead a team and process for collaborating with human pharma and biopharma to identify, transfer and develop human medicines for veterinary use.
- Increased pipeline value by over 50%, and number of projects and project
progression by 300%, with a neutral headcount target.
- Site leader for a GXP R&D facility (90,000 square feet)
- Member of the R&D Leadership Team and the BI Extended Leadership Team with responsibility for the execution of R&D and business strategy.
Atsushi Nagahisa
Atsushi Nagahisa, Ph.D., is President of DNA Partners LLC. Prior to forming DNA Partners, Dr. Nagahisa served on the Board of Directors of RaQualia Pharma Inc. (RaQualia), a biopharmaceutical venture he founded in 2008. He served as Representative Director, President and CEO of RaQualia from its inception through August 2012. Dr. Nagahisa raised $111 million to launch RaQualia, the first, organic spin-out in Pfizer’s history, and then in July 2011 successfully raised an additional $83 million in a public offering (IPO) on the Osaka Securities Exchange JASDAQ Growth Market. Under his leadership, RaQualia established over 300 collaborations and partnerships with institutions and corporations in 17 countries around the world. Galliprant® (grapiprant tablets) and ENTYCE® (capromorelin oral solution), approved by the U.S. Food and Drug Administration in March 2016 and May 2016, respectively, were the result of licensing deals completed between RaQualia and Aratana Therapeutics, Inc. in December 2010.
Steven St. Peter
Steven St. Peter, M.D. is one of our founders and has served as our President and Chief Executive Officer since September 2012. He has been a member of our Board of Directors since December 2010 and served as the Chairman of our Board of Directors from December 2010 to September 2012. Dr. St. Peter was a Managing Director of MPM Asset Management LLC from January 2004 to May 2012, where he focused his investments on both venture and buyout transactions across the pharmaceuticals and medical technology industries. He has previous investment experience from Apax Partners and The Carlyle Group, two private equity firms. Dr. St. Peter was previously an Assistant Clinical Professor of medicine at Columbia University. He received his M.D. from Washington University and completed his residency and fellowship at the Hospital of the University of Pennsylvania. Prior to his medical training, he was an investment banker at Merrill Lynch. Dr. St. Peter also holds an M.B.A. from the Wharton School of Business at the University of Pennsylvania and a B.A. in Chemistry from the University of Kansas. Dr. St. Peter has served as a director of PharmAthene, Inc., a publicly-traded biodefense company, since August 2007 and is currently a member of its governance and nominating committee. Dr. St. Peter has also served as a member of the Board of Directors of the Kansas City Area Life Sciences Institute since March 2014 and as a member of the Board of Directors of the Greater Kansas City Foundation since November 2015. Dr. St. Peter’s previous board experience includes MPM Acquisition Corp., Proteon Therapeutics, Inc., Rhythm Pharmaceuticals, Inc. and Syndax Pharmaceuticals, Inc.